American scientists have developed a patent-free coronavirus vaccine
A group of doctors from the Texas Children’s Hospital, together with colleagues from Baylor College of Medicine (BSM), presented a truly generous gift to all mankind by developing a patent-free anti-coronavirus vaccine Corbevax.
Tests with the participation of volunteers gave a good result – the vaccine showed high efficacy and safety. Moreover, India has expressed its readiness to provide Biological E’s production facilities for the production of more than 100 million doses per month.
Corbevax is based on a traditional viral protein technology that has been used for several decades. Scientists have used the gene encoding this protein to create yeast, from which it is produced on an industrial scale.
The resulting proteins, after collection and purification, are mixed with an adjuvant – a compound that helps to strengthen the immune response. This technology has been used for many years to create an anti-hepatitis vaccine.
Corbevax’s performance indicators have already been compared with the Indian Covishield vaccine. The result is that the new vaccine has a much smaller number of “side effects” and demonstrates a very good immune response, which allows it to resist the delta strain with 80 percent efficiency.
Peter Hotez, who heads the project, said that the patent-free technology is a “gift to the world” that has already been provided to several Asian countries, including India, which was the first to issue an emergency permit for the production of the vaccine by Biological E, which has already produced 150 million doses. In the future, it will produce up to 100 million doses per month.